Publication Date
| In 2025 | 0 |
| Since 2024 | 0 |
| Since 2021 (last 5 years) | 0 |
| Since 2016 (last 10 years) | 2 |
| Since 2006 (last 20 years) | 23 |
Descriptor
| Drug Therapy | 30 |
| Adolescents | 16 |
| Symptoms (Individual… | 16 |
| Children | 15 |
| Outcomes of Treatment | 15 |
| Depression (Psychology) | 10 |
| Safety | 7 |
| Attention Deficit… | 6 |
| Autism | 6 |
| Attention Deficit Disorders | 5 |
| Hyperactivity | 5 |
| More ▼ | |
Source
Author
Publication Type
| Journal Articles | 30 |
| Reports - Research | 19 |
| Reports - Evaluative | 7 |
| Opinion Papers | 2 |
| Information Analyses | 1 |
| Reports - Descriptive | 1 |
Education Level
| High Schools | 1 |
| Junior High Schools | 1 |
| Kindergarten | 1 |
| Preschool Education | 1 |
Audience
| Researchers | 1 |
Location
Laws, Policies, & Programs
Assessments and Surveys
| Aberrant Behavior Checklist | 1 |
| Strengths and Difficulties… | 1 |
What Works Clearinghouse Rating
Peer reviewed
Direct linkSchroder, Carmen M.; Malow, Beth A.; Maras, Athanasios; Melmed, Raun D.; Findling, Robert L.; Breddy, John; Nir, Tali; Shahmoon, Shiri; Zisapel, Nava; Gringras, Paul – Journal of Autism and Developmental Disorders, 2019
A randomized, 13-weeks, placebo-controlled double-blind study in 125 subjects aged 2-17.5 years with Autism Spectrum Disorder or Smith-Magenis syndrome and insomnia demonstrated efficacy and safety of easily-swallowed prolonged-release melatonin mini-tablets (PedPRM; 2-5 mg) in improving sleep duration and onset. Treatment effects on child…
Descriptors: Autism, Pervasive Developmental Disorders, Genetic Disorders, Sleep
Loebel, Antony; Brams, Matthew; Goldman, Robert S.; Silva, Robert; Hernandez, David; Deng, Ling; Mankoski, Raymond; Findling, Robert L. – Journal of Autism and Developmental Disorders, 2016
The aim of this study was to evaluate the short-term efficacy and safety of lurasidone in treating irritability associated with autistic disorder. In this multicenter trial, outpatients age 6-17 years who met DSM-IV-TR criteria for autistic disorder, and who demonstrated irritability, agitation, and/or self-injurious behaviors were randomized to…
Descriptors: Autism, Pervasive Developmental Disorders, Drug Therapy, Psychological Patterns
Katic, Alain; Ginsberg, Lawrence; Jain, Rakesh; Adeyi, Ben; Dirks, Bryan; Babcock, Thomas; Scheckner, Brian; Richards, Cynthia; Lasser, Robert; Turgay, Atilla; Findling, Robert L. – Journal of Attention Disorders, 2012
Objective: To describe clinically relevant effects of lisdexamfetamine dimesylate (LDX) on emotional expression (EE) in children with ADHD. Method: Children with ADHD participated in a 7-week, open-label, LDX dose-optimization study. Expression and Emotion Scale for Children (EESC) change scores were analyzed post hoc using two methods to…
Descriptors: Measurement, Error of Measurement, Emotional Response, Drug Therapy
Findling, Robert L.; Childress, Ann C.; Cutler, Andrew J.; Gasior, Maria; Hamdani, Mohamed; Ferreira-Cornwell, M. Celeste; Squires, Liza – Journal of the American Academy of Child & Adolescent Psychiatry, 2011
Objective: To examine lisdexamfetamine dimesylate (LDX) efficacy and safety versus placebo in adolescents with attention-deficit/hyperactivity disorder (ADHD). Method: Adolescents (13 through 17) with at least moderately symptomatic ADHD (ADHD Rating Scale IV: Clinician Version [ADHD-RS-IV] score greater than or equal to 28) were randomized to…
Descriptors: Attention Deficit Hyperactivity Disorder, Safety, Rating Scales, Adolescents
Findling, Robert L.; Johnson, Jacqueline L.; McClellan, Jon; Frazier, Jean A.; Vitiello, Benedetto; Hamer, Robert M.; Lieberman, Jeffrey A.; Ritz, Louise; McNamara, Nora K.; Lingler, Jacqui; Hlastala, Stefanie; Pierson, Leslie; Puglia, Madeline; Maloney, Ann E.; Kaufman, Emily Michael; Noyes, Nancy; Sikich, Linmarie – Journal of the American Academy of Child & Adolescent Psychiatry, 2010
Objective: To examine the long-term safety and efficacy of three antipsychotics in early-onset schizophrenia spectrum disorders. Method: Patients (8 to 19 years old) who had improved during an 8-week, randomized, double-blind acute trial of olanzapine, risperidone, or molindone (plus benztropine) were eligible to continue on the same medication…
Descriptors: Maintenance, Safety, Schizophrenia, Drug Therapy
Townsend, Lisa; Floersch, Jerry; Findling, Robert L. – Journal of Mixed Methods Research, 2010
Adolescents are routinely treated with psychiatric medications; however, little is known about their attitudes toward pharmacological intervention. The authors used a concurrent triangulation, mixed methods design to assess whether the Drug Attitude Inventory (DAI), developed for adults, is suitable for measuring adolescent attitudes toward…
Descriptors: Adolescent Attitudes, Adolescents, Drug Therapy, Attitude Measures
Manos, Michael J.; Brams, Matthew; Childress, Ann C.; Findling, Robert L.; Lopez, Frank A.; Jensen, Peter S. – Journal of Attention Disorders, 2011
Objective: To summarize the literature investigating changes in emotional expression (EE) as a function of pharmacotherapy in the treatment of ADHD and to differentiate emotional effects related to ADHD pharmacotherapy from emotional effects related to ADHD as a disorder. Method: English language articles published from January 1, 1988, through…
Descriptors: Literature Reviews, Journal Articles, Attention Deficit Disorders, Hyperactivity
Findling, Robert L.; Brams, Matthew; Childress, Ann C.; Lopez, Frank A.; Manos, Michael J.; Jensen, Peter S. – Journal of Attention Disorders, 2011
ADHD is one of the most common neurobehavioral disorders of childhood, and FDA-approved medications offer an efficacious treatment option. However, case reports and anecdotal sources suggest that children can have emotional responses, both salutary and detrimental, to these agents. We have previously conducted a comprehensive literature review and…
Descriptors: Attention Deficit Hyperactivity Disorder, Research Methodology, Drug Therapy, Emotional Response
Rowles, Brieana M.; Findling, Robert L. – Developmental Disabilities Research Reviews, 2010
Developmental disorders such as subaverage intelligence, pervasive developmental disorders, and genetic syndromes are frequently associated with comorbid attention-deficit/hyperactivity disorder (ADHD) or ADHD-like symptoms. While there are not pharmacological cures for these developmental disorders, coinciding ADHD and ADHD-like symptoms that…
Descriptors: Pervasive Developmental Disorders, Attention Deficit Hyperactivity Disorder, Symptoms (Individual Disorders), Drug Therapy
Faraone, Stephen V.; Glatt, Stephen J.; Bukstein, Oscar G.; Lopez, Frank A.; Arnold, L. Eugene; Findling, Robert L. – Journal of Attention Disorders, 2009
Objective: Methylphenidate is a leading first-line treatment for ADHD (AD/HD). This stimulant has long been suspected to adversely affect sleeping patterns of treated individuals, especially children. There are few studies on the effects of recently developed longer-acting methylphenidate treatments, such as once-daily oral or transdermal…
Descriptors: Sleep, Attention Deficit Hyperactivity Disorder, Severity (of Disability), Drug Therapy
Danner, Stephanie; Fristad, Mary A.; Arnold, L. Eugene; Youngstrom, Eric A.; Birmaher, Boris; Horwitz, Sarah M.; Demeter, Christine; Findling, Robert L.; Kowatch, Robert A. – Clinical Child and Family Psychology Review, 2009
Since the mid 1990s, early-onset bipolar spectrum disorders (BPSDs) have received increased attention in both the popular press and scholarly press. Rates of diagnosis of BPSD in children and adolescents have increased in inpatient, outpatient, and primary care settings. BPSDs remain difficult to diagnose, particularly in youth. The current…
Descriptors: Clinical Diagnosis, Adolescents, Puberty, Depression (Psychology)
Townsend, Lisa; Floersch, Jerry; Findling, Robert L. – Journal of Child Psychology and Psychiatry, 2009
Background: Despite the effectiveness of psychotropic treatment for alleviating symptoms of psychiatric disorders, youth adherence to psychotropic medication regimens is low. Adolescent adherence rates range from 10-80% (Swanson, 2003; Cromer & Tarnowski, 1989; Lloyd et al., 1998; Brown, Borden, and Clingerman, 1985; Sleator, 1985) depending on…
Descriptors: Legal Problems, Substance Abuse, Structural Equation Models, Mental Disorders
Feeny, Norah C.; Silva, Susan G.; Reinecke, Mark A.; McNulty, Steven; Findling, Robert L.; Rohde, Paul; Curry, John F.; Ginsburg, Golda S.; Kratochvil, Christopher J.; Pathak, Sanjeev M.; May, Diane E.; Kennard, Betsy D.; Simons, Anne D.; Wells, Karen C.; Robins, Michele; Rosenberg, David; March, John S. – Journal of Clinical Child and Adolescent Psychology, 2009
This article explores aspects of family environment and parent-child conflict that may predict or moderate response to acute treatments among depressed adolescents (N = 439) randomly assigned to fluoxetine, cognitive behavioral therapy, their combination, or placebo. Outcomes were Week 12 scores on measures of depression and global impairment. Of…
Descriptors: Conflict, Cognitive Restructuring, Adolescents, Family Environment
Findling, Robert L.; Short, Elizabeth J.; McNamara, Nora K.; Demeter, Christine A.; Stansbrey, Robert J.; Gracious, Barbara L.; Whipkey, Resaca; Manos, Michael J.; Calabrese, Joseph R. – Journal of the American Academy of Child & Adolescent Psychiatry, 2007
The short-term efficacy of methylphenidate in the treatment of youths aged 5 to 17 years with bipolar disorder (BD) and comorbid attention deficit/hyperactivity disorder (ADHD) was investigated. The trial observation showed that euthymic youths with BD and ADHD might benefit from short-term concomitant treatment with methylphenidate.
Descriptors: Hyperactivity, Attention Deficit Disorders, Depression (Psychology), Children
Findling, Robert L.; Frazier, Jean A.; Gerbino-Rosen, Ginny; Kranzler, Harvey N.; Kumra, Sanjiv; Kratochvil, Christopher J. – Journal of the American Academy of Child & Adolescent Psychiatry, 2007
This article presents responses to the question of whether clozapine is ever appropriate to use in the pediatric population. Among others, Jean A. Frazier also agreed that clozapine is appropriate for use in the pediatric population. Clozapine has truly revolutionized the treatment of refractory patients with schizophrenia at any age. This agent…
Descriptors: Patients, Adolescents, Schizophrenia, Pediatrics
Previous Page | Next Page »
Pages: 1 | 2
